Readystate Asset Management LP Buys New Stake in Hologic, Inc. $HOLX

Readystate Asset Management LP acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 61,652 shares of the medical equipment provider’s stock, valued at approximately $4,161,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. May Hill Capital LLC boosted its stake in shares of Hologic by 10.4% in the third quarter. May Hill Capital LLC now owns 16,997 shares of the medical equipment provider’s stock valued at $1,147,000 after purchasing an additional 1,596 shares during the period. NEOS Investment Management LLC boosted its position in Hologic by 46.6% in the 3rd quarter. NEOS Investment Management LLC now owns 25,298 shares of the medical equipment provider’s stock valued at $1,707,000 after buying an additional 8,046 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Hologic during the third quarter worth $1,057,000. PNC Financial Services Group Inc. increased its position in shares of Hologic by 4.0% during the third quarter. PNC Financial Services Group Inc. now owns 25,452 shares of the medical equipment provider’s stock worth $1,718,000 after acquiring an additional 990 shares during the period. Finally, GF Fund Management CO. LTD. raised its stake in shares of Hologic by 6.3% in the third quarter. GF Fund Management CO. LTD. now owns 6,150 shares of the medical equipment provider’s stock valued at $415,000 after acquiring an additional 363 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the subject of several recent research reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a research note on Wednesday, October 22nd. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. BTIG Research restated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Finally, Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their target price for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Trading Up 0.1%

NASDAQ HOLX opened at $75.15 on Wednesday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.78 billion, a P/E ratio of 31.31, a P/E/G ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.36. The firm has a 50-day moving average price of $74.90 and a 200 day moving average price of $71.75.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $0.87 earnings per share. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.